ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
PR Newswire
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025
Company continues to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025.
"We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps towards a decision and hope to share an update in the near future."
Second Quarter 2025 and Recent Updates
-- ESSA continues to evaluate a range of strategic options focused on
maximizing shareholder value. These options may include, but are not
limited to, a merger, amalgamation, take-over, business combination,
asset sale or acquisition, shareholder distribution, wind-up, liquidation
and dissolution, or other strategic direction. The process is expected to
involve continuing headcount and other cost reductions.
Summary of Financial Results
(Amounts expressed in U.S. dollars)
-- Net Loss. ESSA recorded a net loss of $6.4 million for the second quarter
ended March 31, 2025, compared to $9.0 million for the second quarter
ended March 31, 2024. Investment and other income was $1.0 million for
the second quarter ended March 31, 2025, compared to $1.5 million for the
second quarter ended March 31, 2024.
-- Research and Development ("R&D") expenditures. R&D expenditures for the
second quarter ended March 31, 2025 were $3.5 million compared to $6.2
million for the second quarter ended March 31, 2024, and include non-cash
costs related to share-based payments of $551,433 for the second quarter
ended 2025 compared to $455,903 for the second quarter ended 2024. The
increase in the second quarter was primarily attributed to the wind-down
of clinical trials and cessation of preclinical work.
-- General and Administration ("G&A") expenditures. G&A expenditures for the
second quarter ended March 31, 2025 were $3.9 million compared to $4.3
million for the second quarter ended March 31, 2024 and include non-cash
costs related to share-based payments of $620,676 for the second quarter
ended 2025 compared to $671,710 for the second quarter ended 2024.
Liquidity and Outstanding Share Capital
-- As of March 31, 2025, the Company had available cash reserves and
short-term investments of $113.9 million and net working capital of
$113.5 million. The company has no long-term debt facilities.
-- As of March 31, 2025, the Company had 44,388,550 common shares issued and
outstanding, and there were 2,920,000 common shares issuable upon the
exercise of prefunded warrants at an exercise price of $0.0001.
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the termination of the Company's clinical studies of masofaniten, the Company's evaluation of its strategic alternatives and future announcements in connection therewith and the Company's expected headcount and cost reductions.
Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining necessary regulatory approvals; (iii) ESSA's ability to efficiently wind down its clinical trial activities (iv) that one or more strategic options may be available to ESSA at reasonably acceptable terms; and (v) general business, market and economic conditions.
Forward-looking statements are developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December 17, 2024, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
Contacts
ESSA Pharma Inc.
David Wood, Chief Financial Officer
778.331.0962
dwood@essapharma.com
Investors and Media
Argot Partners
212.600.1902
essa@argotpartners.com
ESSA PHARMA INC.
CONSOLIDATED BALANCE SHEETS
Unaudited
Amounts in thousands of United States dollars
March 31, September 30,
2025 2024
--------------- ---------------
Cash $ 86,308 $ 103,710
Prepaids and other assets 29,107 24,402
--------------- ---------------
Total assets $ 115,415 $ 128,112
Current liabilities 1,714 3,301
Long-term debt 154 205
Shareholders' equity 113,547 124,606
--------------- ---------------
Total liabilities and shareholders' equity $ 115,415 $ 128,112
=========================================== =============== ===============
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
Amounts in thousands of United States dollars, except share and per share data
Three months
ended March 31, Three months ended Six months ended Six months ended
2025 March 31, 2024 March 31, 2025 March 31, 2024
----------------- -------------------- -------------------- --------------------
OPERATING EXPENSES
Research and
development $ 3,484 $ 6,178 $ 8,959 $ 11,555
General and
administration 3,897 4,316 8,108 6,533
----------------- -------------------- -------------------- --------------------
Total operating
expenses (7,381) (10,494) (17,067) (18,088)
----------------- -------------------- -------------------- --------------------
Interest and
other items 1,007 1,504 2,160 3,134
----------------- -------------------- -------------------- --------------------
Net loss for the
period (6,374) (8,990) (14,907) (14,954)
OTHER
COMPREHENSIVE
LOSS
Unrealized gain
(loss) on
short-term
investments (18) (1) (27) 19
----------------- -------------------- -------------------- --------------------
Net loss and
comprehensive
loss for the
period $ (6,392) $ (8,991) $ (14,934) $ (14,935)
Basic and diluted
loss per common
share $ (0.14) $ (0.20) $ (0.34) $ (0.34)
================== ================= ==================== ==================== ==================== Weighted average number of common shares outstanding 44,388,550 44,237,124 44,388,550 44,183,013 ================== ================= ==================== ==================== ====================
View original content:https://www.prnewswire.com/news-releases/essa-pharma-reports-financial-results-for-fiscal-second-quarter-ended-march-31-2025-302449410.html
SOURCE ESSA Pharma Inc
(END) Dow Jones Newswires
May 08, 2025 07:00 ET (11:00 GMT)